RT @schrag_matthew
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:

"It is time to close the book on the amyloid hypothesis", it is one of the conclusions. Good thread.
---
RT @schrag_matthew
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:
https://twitter.com/schrag_matthew/status/1597860167806111744

RT @schrag_matthew@twitter.com

My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM@twitter.com. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:

🐦🔗: https://twitter.com/schrag_matthew/status/1597860167806111744

RT @schrag_matthew
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points: